Triple-Drug immunotherapy cocktail shows promise in advanced tumors
NCT ID NCT03459222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, advanced tumors were enrolled. The main goals were to check for serious side effects and to see how many patients had their tumors shrink or stabilize.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
relatlimab (an experimental immunotherapy) combined with nivolumab, BMS-986205, or ipilimumab
What this could lead to
If successful, this could point toward new combination immunotherapy options for people with advanced cancers that are hard to treat.
What could go wrong
This is an early-phase trial focused on safety, so it is too soon to know if these combinations will work better than existing treatments. Side effects from combining multiple immunotherapies can be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Germantown, Tennessee, 38138, United States
-
Local Institution - 0003
Aurora, Colorado, 80045, United States
-
Local Institution - 0004
Baltimore, Maryland, 21231, United States
-
Local Institution - 0005
St Louis, Missouri, 63110, United States
-
Local Institution - 0006
Duarte, California, 91010, United States
-
Local Institution - 0007
Zurich, 8091, Switzerland
-
Local Institution - 0008
Lausanne, 1011, Switzerland
-
Local Institution - 0009
Naples, 80131, Italy
-
Local Institution - 0010
Forlì, 47014, Italy
-
Local Institution - 0011
Nedlands, Western Australia, 6009, Australia
-
Local Institution - 0012
Wollstonecraft, New South Wales, 2065, Australia
-
Local Institution - 0013
Headington, OX3 7LE, United Kingdom
-
Local Institution - 0014
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Local Institution - 0015
Villejuif, 94800, France
-
Local Institution - 0016
Toulouse, 31059, France
-
Local Institution - 0017
Marseille, 13385, France
-
Local Institution - 0018
Madrid, 28050, Spain
-
Local Institution - 0019
Barcelona, 08036, Spain
-
Local Institution - 0020
Pamplona, 31008, Spain
-
Local Institution - 0021
Madrid, 28041, Spain
-
Local Institution - 0022
Málaga, 29011, Spain
-
Local Institution - 0023
Rome, 00144, Italy